Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume Two: Diagnosis, Therapeutic Targets and Molecular Mechanisms for Hepatocellular Carcinoma Progression provides comprehensive information about ongoing research and clinical data surrounding liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. The volume discusses topics such as computational approaches for identification of biomarkers, enzymes and pathways of HCC, circulating and epigenetic biomarkers, drug resistance, metabolic pathways, and small molecule-target therapies. In addition, it discusses immunotherapies, immune check point inhibitors and nanotechnology-based therapies.
This book is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.
1. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2 - p. Page i 2. Cover - p. Page i 3. Title page - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iii 6. Dedication - p. Page v 7. Contents - p. Page vii 8. List of contributors - p. Page viii 9. About the editors - p. Page viii 10. Preface - p. Page x 11. List of Illustrations - p. Page xiii 12. List of Tables - p. Page xiv 13. Chapter 1 : Hepatocellular carcinoma diagnosis - p. Page xiv 14. Chapter 2 : Computational analysis of prognosis-related genes in liver cancer - p. Page 4 15. Chapter 3 : Computational approaches to identify biomarkers, enzymes, and pathways of hepatocellular carcinoma - p. Page 17 16. Chapter 4 : Ribonucleic acid sequence analysis in deciphering hepatocellular carcinoma - p. Page 30 17. Chapter 5 : Hepatocarcinogenesis and the role of next-generation sequencing in liver cancer - p. Page 43 18. Chapter 6 : Liver cancer: the tumor microenvironment and associated pathways - p. Page 55 19. Chapter 7 : Metabolic pathway-based target therapy to hepatocellular carcinoma: a computational approach - p. Page 73 20. Chapter 8 : Targeting ion channels in hepatic cancer - p. Page 96 21. Chapter 9 : Tyrosine kinases: their role in hepatocellular carcinoma - p. Page 127 22. Chapter 10 : Role of transcription factors in hepatocellular carcinoma - p. Page 145 23. Chapter 11 : Modulatory act of diverse transcriptional factors in liver carcinoma - p. Page 159 24. Chapter 12 : Association of specificity protein 1 with hepatocellular carcinoma - p. Page 177 25. Chapter 13 : Promising biomarkers for liver cancer - p. Page 192 26. Chapter 14 : Molecular signaling and its role in drug resistance in hepatocellular carcinomas - p. Page 204 27. Chapter 15 : Multidrug resistance, a major obstacle in hepatocellular carcinoma treatment: challenges and future perspectives - p. Page 220 28. Chapter 16 : Proliferative signaling pathways in hepatocellular carcinoma - p. Page 246 29. Chapter 17 : Targeting angiogenesis in hepatocellular carcinoma - p. Page 265 30. Chapter 18 : Conventional and novel biomarkers for the diagnosis and prognosis of liver cancer - p. Page 278 31. Chapter 19 : Updates on the staging and treatment of hepatocellular carcinoma - p. Page 301 32. Chapter 20 : ROS-mediated pathways: potential role in hepatocellular carcinoma biology and therapy - p. Page 316 33. Chapter 21 : Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes and therapeutic options - p. Page 331 34. Chapter 22 : LKB1/STK11-mediated signal transduction in hepatocellular carcinoma - p. Page 349 35. Index - p. Page 365
Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume Two: Diagnosis, Therapeutic Targets and Molecular Mechanisms for Hepatocellular Carcinoma Progression provides comprehensive information about ongoing research and clinical data surrounding liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. The volume discusses topics such as computational approaches for identification of biomarkers, enzymes and pathways of HCC, circulating and epigenetic biomarkers, drug resistance, metabolic pathways, and small molecule-target therapies. In addition, it discusses immunotherapies, immune check point inhibitors and nanotechnology-based therapies.
This book is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.
1. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2 - p. Page i 2. Cover - p. Page i 3. Title page - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iii 6. Dedication - p. Page v 7. Contents - p. Page vii 8. List of contributors - p. Page viii 9. About the editors - p. Page viii 10. Preface - p. Page x 11. List of Illustrations - p. Page xiii 12. List of Tables - p. Page xiv 13. Chapter 1 : Hepatocellular carcinoma diagnosis - p. Page xiv 14. Chapter 2 : Computational analysis of prognosis-related genes in liver cancer - p. Page 4 15. Chapter 3 : Computational approaches to identify biomarkers, enzymes, and pathways of hepatocellular carcinoma - p. Page 17 16. Chapter 4 : Ribonucleic acid sequence analysis in deciphering hepatocellular carcinoma - p. Page 30 17. Chapter 5 : Hepatocarcinogenesis and the role of next-generation sequencing in liver cancer - p. Page 43 18. Chapter 6 : Liver cancer: the tumor microenvironment and associated pathways - p. Page 55 19. Chapter 7 : Metabolic pathway-based target therapy to hepatocellular carcinoma: a computational approach - p. Page 73 20. Chapter 8 : Targeting ion channels in hepatic cancer - p. Page 96 21. Chapter 9 : Tyrosine kinases: their role in hepatocellular carcinoma - p. Page 127 22. Chapter 10 : Role of transcription factors in hepatocellular carcinoma - p. Page 145 23. Chapter 11 : Modulatory act of diverse transcriptional factors in liver carcinoma - p. Page 159 24. Chapter 12 : Association of specificity protein 1 with hepatocellular carcinoma - p. Page 177 25. Chapter 13 : Promising biomarkers for liver cancer - p. Page 192 26. Chapter 14 : Molecular signaling and its role in drug resistance in hepatocellular carcinomas - p. Page 204 27. Chapter 15 : Multidrug resistance, a major obstacle in hepatocellular carcinoma treatment: challenges and future perspectives - p. Page 220 28. Chapter 16 : Proliferative signaling pathways in hepatocellular carcinoma - p. Page 246 29. Chapter 17 : Targeting angiogenesis in hepatocellular carcinoma - p. Page 265 30. Chapter 18 : Conventional and novel biomarkers for the diagnosis and prognosis of liver cancer - p. Page 278 31. Chapter 19 : Updates on the staging and treatment of hepatocellular carcinoma - p. Page 301 32. Chapter 20 : ROS-mediated pathways: potential role in hepatocellular carcinoma biology and therapy - p. Page 316 33. Chapter 21 : Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes and therapeutic options - p. Page 331 34. Chapter 22 : LKB1/STK11-mediated signal transduction in hepatocellular carcinoma - p. Page 349 35. Index - p. Page 365
